

# Mehdi Farokhnia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7613421/publications.pdf>

Version: 2024-02-01

56  
papers

2,233  
citations

201385

27  
h-index

233125

45  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2671  
citing authors

#	ARTICLE	IF	CITATIONS
1	N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia. <i>Clinical Neuropharmacology</i> , 2013, 36, 185-192.	0.2	121
2	Education Attainment and Alcohol Binge Drinking: Diminished Returns of Hispanics in Los Angeles. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2019, 9, 9.	1.0	118
3	Comparing the efficacy and safety of <i>Crocus sativus</i> L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. <i>Human Psychopharmacology</i> , 2014, 29, 351-359.	0.7	114
4	A randomized, double-blind, clinical trial comparing the efficacy and safety of <i>Crocus sativus</i> L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. <i>Journal of Affective Disorders</i> , 2014, 155, 216-222.	2.0	111
5	PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. <i>Depression and Anxiety</i> , 2015, 32, 167-173.	2.0	94
6	The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. <i>Molecular Psychiatry</i> , 2020, 25, 461-475.	4.1	90
7	Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. <i>Psychiatry Research</i> , 2014, 215, 540-546.	1.7	87
8	N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism. <i>Clinical Neuropharmacology</i> , 2015, 38, 11-17.	0.2	86
9	Exogenous ghrelin administration increases alcohol self-administration and modulates brain functional activity in heavy-drinking alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2018, 23, 2029-2038.	4.1	82
10	Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1428-1433.	1.1	81
11	Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder. <i>Physiology and Behavior</i> , 2019, 204, 49-57.	1.0	80
12	Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. <i>Bipolar Disorders</i> , 2015, 17, 606-614.	1.1	78
13	The Role of the Ghrelin System in Drug Addiction. <i>International Review of Neurobiology</i> , 2017, 136, 89-119.	0.9	74
14	Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review. <i>Pharmacological Reviews</i> , 2022, 74, 119-140.	7.1	72
15	The Microbiota, the Gut and the Brain in Eating and Alcohol Use Disorders: A <i>“MÃ©nage Ã Trois”</i> . <i>Alcohol and Alcoholism</i> , 2017, 52, 403-413.	0.9	66
16	Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2014, 28, 677-685.	2.0	62
17	Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. <i>Journal of Psychopharmacology</i> , 2015, 29, 575-581.	2.0	60
18	A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. <i>Psychiatry Research</i> , 2015, 229, 181-187.	1.7	53

#	ARTICLE	IF	CITATIONS
19	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. <i>Translational Psychiatry</i> , 2020, 10, 71.	2.4	48
20	Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial. <i>Paediatric Drugs</i> , 2013, 15, 505-514.	1.3	47
21	Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 650-656.	1.1	47
22	Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism. <i>Clinical Neuropharmacology</i> , 2013, 36, 179-184.	0.2	44
23	The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. <i>Human Psychopharmacology</i> , 2016, 31, 103-112.	0.7	41
24	Substance Use among Economically Disadvantaged African American Older Adults; Objective and Subjective Socioeconomic Status. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1826.	1.2	40
25	A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. <i>Psychopharmacology</i> , 2013, 228, 595-602.	1.5	36
26	A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. <i>Psychopharmacology</i> , 2014, 231, 533-542.	1.5	34
27	l-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial. <i>Journal of Psychiatric Research</i> , 2014, 59, 125-131.	1.5	30
28	Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats. <i>Frontiers in Neuroscience</i> , 2020, 14, 599646.	1.4	30
29	Prospects for pharmacotherapies to treat alcohol use disorder. <i>Current Opinion in Psychiatry</i> , 2019, 32, 255-265.	3.1	25
30	A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. <i>Molecular Psychiatry</i> , 2021, 26, 545-555.	4.1	21
31	Cardiovascular considerations in antidepressant therapy: an evidence-based review. <i>The Journal of Tehran Heart Center</i> , 2013, 8, 169-76.	0.3	21
32	Impulsive Personality Traits Mediate the Relationship Between Adult Attention-Deficit/Hyperactivity Symptoms and Alcohol Dependence Severity. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 173-183.	1.4	20
33	Pharmacological manipulation of the ghrelin system and alcohol hangover symptoms in heavy drinking individuals: Is there a link?. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 172, 39-49.	1.3	19
34	Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers. <i>Neuropharmacology</i> , 2020, 170, 107788.	2.0	19
35	Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 846-855.	0.3	17
36	A closer look at alcohol-induced changes in the ghrelin system: novel insights from preclinical and clinical data. <i>Addiction Biology</i> , 2022, 27, e13033.	1.4	17

#	ARTICLE	IF	CITATIONS
37	Extracellular esterase activity as an indicator of endoplasmic reticulum calcium depletion. <i>Biomarkers</i> , 2018, 23, 756-765.	0.9	15
38	Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies. <i>Brain Research</i> , 2020, 1740, 146851.	1.1	13
39	Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study. <i>Neuropharmacology</i> , 2019, 158, 107711.	2.0	11
40	Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 464-476.	1.0	11
41	The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1220-1227.	1.4	10
42	Identifying and Characterizing Subpopulations of Heavy Alcohol Drinkers Via a Sucrose Preference Test: A Sweet Road to a Better Phenotypic Characterization?. <i>Alcohol and Alcoholism</i> , 2018, 53, 560-569.	0.9	10
43	Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. <i>Neuropsychopharmacology</i> , 2021, 46, 2140-2147.	2.8	9
44	Blood Biomarkers of Alcohol Use: A Scoping Review. <i>Current Addiction Reports</i> , 2021, 8, 500-508.	1.6	9
45	Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. <i>BJPsych International</i> , 2022, 19, 66-69.	0.8	9
46	Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment. <i>Neuropharmacology</i> , 2018, 137, 230-239.	2.0	8
47	Effect of oral alcohol administration on plasma cytokine concentrations in heavy drinking individuals. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108771.	1.6	8
48	OUP accepted manuscript. <i>Alcohol and Alcoholism</i> , 2021, , .	0.9	8
49	Investigating the link between serum concentrations of brain-derived neurotrophic factor and behavioral measures in anxious alcohol-dependent individuals. <i>Alcohol</i> , 2020, 89, 75-83.	0.8	6
50	The Promise of Neuroimmune Targets for Treating Drug Addiction and Other Psychiatric Disorders: Granulocyte-Colony Stimulating Factor Exemplification. <i>Frontiers in Psychiatry</i> , 2020, 11, 220.	1.3	5
51	A population-based investigation of the association between alcohol intake and serum total ghrelin concentrations among cigarette-smoking, non-alcohol-dependent male individuals. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108835.	1.6	4
52	Leptin Gene and Leptin Receptor Gene Polymorphisms in Alcohol Use Disorder: Findings Related to Psychopathology. <i>Frontiers in Psychiatry</i> , 2021, 12, 723059.	1.3	3
53	Effect of intravenous ghrelin administration, combined with alcohol, on circulating metabolome in heavy drinking individuals with alcohol use disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 2207-2216.	1.4	3
54	The Mineralocorticoid Receptor: An Emerging Pharmacotherapeutic Target for Alcohol Use Disorder?. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1832-1834.	1.7	3

#	ARTICLE	IF	CITATIONS
55	Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108904.	1.6	2
56	Commentary on Schmitz <i>et al</i> . (2017): Advancing medication development for addiction—behavioral and neuroimaging outcomes as indirect biomarkers of target engagement. <i>Addiction</i> , 2017, 112, 1869-1870.	1.7	1